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DiagnosisCirculating microRNAs (miRNAs) are promising biomarkers for cancer detection. However, multiethnic and
multicentric studies of non-small-cell lung cancer (NSCLC) are lacking. We recruited 221 NSCLC patients, 161
controls and 56 benign nodules from both China and America. Initial miRNA screening was performed using
the TaqMan Low Density Array followed by conﬁrming individually by RT-qPCR in Chinese cohorts. Finally, we
performed a blind trial from an American cohort to validate our ﬁndings. RT-qPCR conﬁrmed that miR-483-5p,
miR-193a-3p, miR-25, miR-214 and miR-7 were signiﬁcantly elevated in patients compared to controls. The
areas under the curve (AUCs) of the ROC curve of this ﬁve-serum miRNA panel were 0.976 (95% CI, 0.939–1.0;
P b 0.0001) and 0.823 (95% CI, 0.75–0.896; P b 0.0001) for the two conﬁrmation sets, respectively. In the blind
trial, the panel correctly classiﬁed 95% NSCLC cases and 84% controls from the American cohort. Most important-
ly, the panel was capable of distinguishing NSCLC from benign nodules with an AUC of 0.979 (95% CI, 0.959–1.0)
in the American cohort and allowed correct prediction of 86% and 95% stage I–II tumors in the Chinese and
American cohorts, respectively. This serum miRNA panel holds the potential for diagnosing ethnically diverse
NSCLC patients.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tumors of the lung are one of the highest incidence of cancers and
the leading cause of cancer deaths worldwide. According to the 2008
WHO epidemiological statistics, the incidence of lung cancer is more
than 130 per 100,000 individuals, which accounts for 13% (1.6 million)
of the total cancer cases and 18% (1.4 million) of cancer-related mortal-
ity; even worse, the number of new cases is expected to doubleell lung cancer; RT-qPCR, quantitativ
TNM, tumor–node–metastasis.
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90%) of lung cancer cases are non-small-cell lung cancer (NSCLC)
(D'Addario et al., 2010). Early-stage NSCLCs are symptom-free and difﬁ-
cult to detect; therefore, the disease is often diagnosed at a locally ad-
vanced or metastatic stage (stage III or stage IV), at which point few
clinical treatment options remain. Despite numerous developments re-
lating to NSCLC therapies in recent years, the overall survival rate of
NSCLC patients has only improved by approximately 15% over the laste reverse transcription polymerase chain reaction; TLDA, TaqMan Low-Density Array; Cq,
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the ﬁve-year survival rate is approximately 33% for cases discovered at
early stages (stage I or II) (Little et al., 2005). At present, diagnosis largely
relies to a large extent on imaging methods, such as chest X-rays, CT
scans, or PET–CT scans, followed by bronchoscopy and biopsy (Oken
et al., 2005; International Early Lung Cancer Action Program
Investigators et al., 2006). While no blood marker for NSCLC is available
at present, some blood-based proteinmarkers such as carcinoembryonic
antigen and squamous cell carcinoma antigen have been applied as
candidate diagnostic markers for NSCLC in clinics. Unfortunately, the
low sensitivity and speciﬁcity of these antigens limit the diagnostic
accuracy and utility. For these reasons, the development of sensitive
and reliable biomarkers remains a major challenge for researchers.
MicroRNAs (miRNAs) are a family of small, single-stranded non-
coding RNAs that are critical regulators of numerous diseases, including
cancer, and their expression patterns have the potential to diagnose
various types of cancer (Esquela-Kerscher & Slack, 2006; Kong et al.,
2012; Calin & Croce, 2006). Recent studies from our group and others
have demonstrated that human body ﬂuid such as serum/plasma
contains numerous stable miRNAs, potentially paving the way toward
a novel class of cancer biomarkers (Chen et al., 2008; Mitchell et al.,
2008; Eichelser et al., 2013). A number of studies have reported that cir-
culating miRNA expression patterns differ between NSCLC patients and
healthy controls, and some dysregulated serum miRNAs hold potential
as promising biomarkers for the diagnosis and prognosis of NSCLC
(Chen et al., 2008; Hu et al., 2010; Bianchi et al., 2011; Chen et al.,
2012a; Heegaard et al., 2012; Wang et al., 2013). However, data
produced by different groups on this topic are quite variable. Therefore,
a systematical analysis of serum miRNA expression proﬁles from
multiethnic and multicentric NSCLC cases is urgently needed.
In the present study, we used a high-throughput TaqMan Low-
Density Array (TLDA) (Applied Biosystems) scanning combined with
an individual quantitative reverse transcription polymerase chain
reaction PCR (RT-qPCR) conﬁrmation to establish a panel of signiﬁcantly
upregulated serummiRNAs in NSCLC patients using samples from three
independent Chinese cohorts. A single-blind trial was then performed to
assess the ability of the panel to diagnose NSCLC in an American cohort
and to function as a reliable diagnostic indicator of NSCLC in patients of
different ethnicities.
2. Materials and Methods
2.1. Participants and Study Design
We totally enrolled 438 participants from both China and America,
including 221 NSCLC patients, 161 normal controls and 56 benign
nodules. To identify a miRNA signature associated with NSCLC, we
ﬁrst used a discovery cohort consisting of 62 individuals (31 patients
with NSCLC and 31 normal controls) from Jinling Hospital, China, to
ﬁnd serum miRNAs as surrogate markers. Subsequently, veriﬁcation
was conducted using individual RT-qPCR assays to reﬁne the number
of serummiRNAs included in the NSCLC signature by a 2-phase experi-
mental procedure from two additionally independent, randomized
Chinese cohorts: one consisted of 19 lung cancer cases (from Cancer
Hospital of Xuzhou) and 19 normal controls (from Jinling Hospital)
and the other consisted of 63 case samples (from Jinling Hospital,
Jiangsu Province Hospital of TCM and Nanjing Chest Hospital) and 63
normal controls (from Jinling Hospital). Finally, we evaluated the
serum samples from an American cohort, which included 108 NSCLC
patients, 48 normal controls and 56 benign nodules (as non-cancer
controls). The American cohort was selected from the Mayo Clinic
(Mayo Validation Support Services, 3050 Superior Drive, NW, Roches-
ter, Minnesota) in a blinded fashion (the investigators performing the
analysis on the blood samples were blinded to the patients' clinical
diagnosis and the medical sample providers conducted the data analy-
sis) to validate the predictive power of the identiﬁed miRNA signaturefor NSCLC. The overall study design is shown in Fig. 1. The protocol
was approved by the ethics committee board at each participating
institution, and written informed consent was obtained from all
participants.
2.2. Eligibility, Exclusion Criteria and Processing of Serum
Histopathological analysis of the tumors was performed according
to the WHO criteria. Patients were eligible if they had been diagnosed
with a pathological NSCLC that met histological or cytological criteria.
The tumor stage at the time of diagnosis was assessed according to
the American Joint Committee on Cancer guidelines (http://www.
cancerstaging.org/). Eligibility criteria for NSCLC patients both China
cohorts and American cohort included: 1) if eighteen years of age old
or older; 2) conﬁrmed diagnosis of NSCLC; 3) not previously suffered
from lung cancer and other types of cancers; 4) not previously with
chemotherapy or radiotherapy; 5) and free of synchronous multiple
cancers. For patients who underwent surgery, deﬁnitive tumor stage
was determined based on the operative ﬁndings. For those patients
unsuitable for surgical therapy, tumors were assessed using histopa-
thology or imaging technology such as bronchoscopy, dynamic comput-
ed tomography (CT), magnetic resonance imaging, and/or endoscopic
ultrasonography. Eligibility criteria for benign nodules enrolled from
American cohort (Mayo Clinic) included: 1) nodules detected on CT
scan; 2) biopsy performed and conﬁrmed negative for cancer or biopsy
performed and nodules detected and were conﬁrmed benign based on
CT scan trial algorithm; 3) ﬁve years of follow-up conﬁrming no
diagnosis of lung cancer; and 4) no previous history of cancer prior to
enrollment. Individuals who showed no evidence of disease during
themedical checkupwere selected as normal controls. Eligibility criteria
for normal controls in American cohort included: 1) no nodules detect-
ed on CT scan; 2) ﬁve years of following up conﬁrming no diagnosis of
lung cancer; and 3) no previous history of cancer prior to enrollment.
The recruitment of normal subjects in Chinese cohorts was conducted
in theHealthy Physical Examination Center of the JinlingHospital (Nan-
jing, China). The ﬁnally selected controls underwent routine laboratory
and imaging tests such as complete blood cell counts, sera biochemical
proﬁle, baseline electrocardiogram, tumor markers (CEA and AFP), a
type-B ultrasound for the abdomen and pelvis, and a chest X-ray. All
the healthy individuals did not have any pulmonary pathology or any
constitutional symptoms after consulting the physical examination re-
cords. Peripheral venous blood (3–4 ml) was collected in serum
vacutainer tubes (Becton, Dickinson and Company, Franklin Lakes,
New Jersey)with clot activator fromparticipants 12 h overnight fasting,
and serum was immediately separated by a 10-min centrifugation at
1500 g. Supernatant serum samples were then carefully transferred to
a new Eppendorf tube and stored at−80 °C until analyze. In addition,
we checked the hemolysis status of all the samples and only the quali-
ﬁed samples were used in our study.
The demographics and clinical features of all NSCLC patients and
controls are shown in Table 1. All blood samples from patients were
gathered before treatments, including surgery, chemotherapy,
radiotherapy, and tissue manipulation (such as biopsy, bronchoscopy,
or ﬁne needle aspiration).
2.3. RNA Isolation, TLDA and RT-qPCR Assays
The serum expression proﬁling of miRNA was scanned using TLDA
on an ABI PRISM 7900HT (Luo et al., 2013). A hydrolysis probe-based
RT-qPCR assay was then used to validate candidate miRNAs following
the manufacturer's instructions as described previously (Luo et al.,
2013). The concentrations of serum miRNAs were normalized to
let-7d/g/i trio and relative levels were evaluated using the comparative
quantiﬁcation cycle (Cq) method (Chen et al., 2013). The details of RNA
isolation, TLDA and RT-qPCR assays are provided in the Supplemental
Methods.
Fig. 1. Overall study design and numbers of patients with NSCLC included in the discovery, training, validation and testing sets.
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The serum miRNA concentrations were represented as the mean
(SE), and the other variableswere expressed as themean (SD). The non-
parametric Mann–Whitney U-test was performed to compare miRNAconcentrations between the groups. The differences in other variables
between the two groups were compared using Student's t-test or two-
sided χ2 test. A P-value b 0.05 was considered statistically signiﬁcant.
We performed a risk score analysis to evaluate the associations between
the concentrations of the serum miRNAs and NSCLC. Brieﬂy, the risk
1380 C. Wang et al. / EBioMedicine 2 (2015) 1377–1385score of each miRNA, denoted as s, was set to 1 if its concentration was
higher than the upper 95% reference interval for the corresponding
miRNA concentration in controls and to 0 otherwise. A risk score func-
tion to predict NSCLC was deﬁned according to a linear combination of
concentration for each miRNA. For example, the RSF for sample i using
information from ﬁve miRNAs was: rsfi =∑5j − 1Wj · sij. In the above
equation, sij is the risk score for miRNA j on sample i, and Wj is the
weight of the risk score of miRNA j. To determine theWs, ﬁve univariate
logistic regressionmodels wereﬁtted using the disease statuswith each
of the risk scores. The regression coefﬁcient of each risk score was used
as the weight to show the contribution of each miRNA to the RSF. We
then constructed the ROC curves to evaluate the speciﬁcity and sensitiv-
ity of NSCLC prediction for each miRNA individually and for the combi-
nation of miRNAs. All analyses above were performed with the use of
SPSS statistical software (version 16.0). Additional details regarding
statistical methods are provided in the Supplemental Methods.
2.5. Funding
This work was supported by the grants from the National Basic
Research Program of China (973 Program) (2014CB542300), the
Research Special Fund for Public Welfare Industry of Health of China
(201302018), the National Natural Science Foundation of China
(81171661, 81472021, 81401257 and 81301511), the Natural Science
Foundation of Jiangsu Province (BK2011013, BK20140730), theMedical
Scientiﬁc Research Foundation of Nanjing Military Command (12Z28),
and the Research Funds of the Jinling Hospital (2014043). The funding
agency has no role in the study design, date analysis, interpretation of
results or writing of this manuscript.
3. Results
3.1. Serum miRNA Screening by TLDA
We globally analyzed the miRNA expression patterns in two pooled
serum samples from 31 NSCLC patients and 31 normal controls in
Chinese cohort 1 using TLDA approach. AmiRNAwas considered upreg-
ulated if its Cq valuewas b25 in theNSCLC sample and its concentration
showed at least a 2-fold increase in the NSCLC sample compared to theTable 1
Demographic and clinical features of the NSCLC patients and controls of the Chinese cohorts an
Variable Chinese cohorts
Cohort 1 Cohort 2
Normal control NSCLC Normal control NSCLC
n = 31 n = 31 n = 19 n = 19
Age — yra 59.8 ± 8.5 59.6 ± 11.5 62.1 ± 9.4 61.8 ± 1
≤59 20 (64.5) 13 (41.9) 10 (52.6) 8 (42.1)
N59 11 (35.5) 18 (58.1) 9 (47.4) 11 (57.9)
Unknown 0 (0) 0 (0) 0 (0) 0 (0)
Sex — no. (%)
Male 25 (80.6) 23 (74.2) 13 (68.4) 11 (57.9)
Female 6 (19.4) 8 (25.8) 6 (31.6) 8 (42.1)
Unknown 0 (0) 0 (0) 0 (0) 0 (0)
Smoking status — no. (%)
Ever and current 12 (38.7) 16 (51.6) 7 (36.8) 8 (42.1)
Never 19 (61.3) 15 (48.4) 12 (63.2) 11 (57.9)
Tumor subtype — no. (%)
Adenocarcinoma – 12 (38.7) – 9 (47.3)
Squamous cell carcinoma 9 (29.0) – 4 (21.1)
Other – 10 (32.3) – 6 (31.6)
TNM stage — no. (%)
I – 7 (22.6) – 1 (5.3)
II – 4 (12.9) – 2 (10.5)
III – 9 (29.0) – 2 (10.5)
IV – 11 (35.5) – 12 (63.2)
Missing data – 0 – 2 (10.5)
a The data are expressed as the mean (SD).control sample. Class-comparison analysis of all 754 miRNAs revealed
that 38 miRNAs (5%) were upregulated in the NSCLC sample (Supple-
mental Table 1), 16 of the upregulatedmiRNAswhich have been report-
ed to be conserved in lung tissue and involved in cell proliferation,
migration, immune related or known as “oncomir” were subsequently
validated in the individual patients using RT-qPCR, while the newly
identiﬁed miRNAs and miRNA-star miRNAs were excluded for further
conﬁrmation.
3.2. Increases in Serum miRNA Concentrations Conﬁrmed by RT-qPCR
The 16 miRNAs selected from the TLDA results were ﬁrst conﬁrmed
in a training set consisting of an independent Chinese cohort including
19 cases and 19 controls (the training set). Nine of the 16 miRNAs
were found to be markedly dysregulated in sera from NSCLC cases. Of
these 9 miRNAs, ﬁve upregulated miRNAs, including miR-483-5p,
miR-193a-3p, miR-214, miR-25, and miR-7, were chosen for further
analysis because the difference between cases and controls was most
signiﬁcant for this set (exhibiting a fold change N 1.5 and a P b 0.05)
(Supplemental Table 2 and Fig. 2). The ﬁve miRNAswere further exam-
ined in another Chinese cohort including 63 cases and 63 controls (the
validation set). The changes in the levels of these ﬁve miRNAs in the
NSCLC group were consistent with those from the training set (fold
change N 1.5 and P b 0.05) (Fig. 2), thus conﬁrming stability of the
production pattern of these miRNAs.
3.3. Assessment of Risk Score in Chinese Cohorts
Next, we conducted ROC curve analyses on each of the individual
ﬁve serum miRNAs to assess the diagnostic value for discriminating
between NSCLCs and normal subjects in the training set. The AUCs for
these miRNAs ranged from 0.609 to 0.900 (Supplemental Table 3). To
clarify the diagnostic capability of the combination of the ﬁve miRNAs,
we conducted a risk score analysis on the data set and used the results
to predict NSCLC case and normal status. When the optimal cutoff
value was 2.617, all of the NSCLC samples (100%) had a risk score N
2.617, whereas only 3 of the 19 controls exhibited a risk score N 2.617
(Table 2). The ROC curve for the panel demonstrated a remarkable
accuracy of diagnosis, evidenced by an AUC of 0.976 (95% CI,d American cohort.
American cohort
Cohort 3 Normal control Benign nodules NSCLC
Normal control NSCLC
n = 63 n = 63 n = 48 n = 56 n = 108
2.7 59.7 ± 5.7 61.9 ± 9.5 58.5 ± 5.1 63.7 ± 6.7 67.2 ± 10.2
36 (57.1) 25 (39.7) 36 (75.0) 15 (26.8) 21 (19.4)
27 (42.9) 38 (60.3) 12 (25.0) 40 (71.4) 87 (80.6)
0 (0) 0 (0) 0 (0) 1 (1.8) 0 (0)
37 (58.7) 49 (77.8) 20 (41.7) 25 (44.6) 52 (48.1)
26 (41.3) 14 (22.2) 28 (58.3) 30 (53.6) 56 (51.9)
0 (0) 0 (0) 0 (0) 1 (1.8) 0 (0)
18 (28.6) 39 (61.9) 48 (100) 55 (98.2) 103 (95.4)
45 (71.4) 24 (38.1) 0 (0) 1 (1.8) 5 (4.6)
– 26 (41.3) – – 52 (48.1)
– 26 (41.3) – – 27 (25.0)
– 11 (17.4) – – 29 (26.9)
– 3 (4.7) – – 43 (39.8)
– 8 (12.7) – – 15 (13.9)
– 9 (14.3) – – 29 (26.9)
– 41 (65.1) – – 17 (15.7)
– 2 (3.2) – – 4 (3.7)
1381C. Wang et al. / EBioMedicine 2 (2015) 1377–13850.939–1.0; P b 0.0001), which was much larger than the AUC values for
each of the ﬁve individual miRNAs (Supplemental Table 3 and Fig. 3A).
Furthermore, at the optimal cutoff value, the diagnostic sensitivity and
speciﬁcity of the ﬁve-miRNA panel for NSCLC diagnosis were 100%
and 84%, respectively (Fig. 3A).
We further evaluated the diagnostic values of the ﬁve individual
miRNAs and the ﬁve-miRNA panel in the validation set. As shown in
Supplemental Table 4, the AUCs for each of the ﬁve miRNAs ranged
from 0.663 to 0.835. At the same cutoff value (2.617), 55 of the 63
NSCLC samples (87%) had a risk score N 2.617 (Table 2). And the
discriminate sensitivity and speciﬁcity of the ﬁve-miRNA panel for
NSCLC were 89% and 68%, respectively, and the AUC was 0.823 (95%
CI, 0.750–0.896; P b 0.0001) (Supplemental Table 4 and Fig. 3B).
3.4. Evaluation of the Predictive Value of the Five-miRNA Panel in an
American Cohort by Blinded Trial
We tested an additional 212 serum samples from an American
cohort in a blind trial using the RT-qPCR assay.We aimed to further con-
ﬁrm the diagnostic accuracy of the ﬁve serummiRNA-based biomarker
for different ethnicities. First, we analyzed the difference in serum con-
centrations of miRNAs between the different ethnicities. We observed
from RT-qPCR data that the Cq values of serum miRNAs in samples
from the American cohort were generally higher than in the Chinese co-
hort by approximately N3 cycles. However, the relative concentrations
of four miRNAs, including miR-483-5p, miR-193a-3p, miR-25 and
miR-7, were comparable between the Chinese and American cohortsFig. 2. The relative contents of the selected ﬁvemiRNAs in the sera from patientwith NSCLC in t
controls (P b 0.05). ⁎P b 0.05; ⁎⁎P b 0.01; ⁎⁎⁎P b 0.001.except miR-214, since the average Cq value of the internal control
let-7d/g/i in the American cohort with a mean (SD) of 24.59 (0.85)
was also approximately 3 cycles higher than that in Chinese cohort
[22.03(0.92)]. These results suggest that the relative concentrations of
the ﬁve selected miRNAs correlate well between different races when
let-7d/g/i is used as an internal reference for the RT-qPCR assay. Subse-
quently, we analyzed the relative levels of the ﬁve miRNAs from the
American cohort and classiﬁed them on the basis of the risk score
model of the ﬁve-miRNA panel, with a cutoff value of 2.617. As a result,
103 of 108 NSCLC samples (95%) and 87 of 104 control samples (84%)
were classiﬁed correctly (Table 2). Of the 104 control samples, 48
were from healthy individuals, and the other 56 were from patients
who had benign lung nodules detected by CT scan and did not develop
lung cancer after a ﬁve-year period of follow-up. The relative concentra-
tions of the ﬁve serum miRNAs were all signiﬁcantly higher in NSCLC
patients than in normal controls and patients with benign nodules (at
least P b 0.001) (Fig. 4).
In the blind American cohort, the AUCs for the ﬁve miRNAs
ranged from 0.696 to 0.964 (Supplemental Table 5). The ﬁve-
miRNA panel was signiﬁcantly reliable when applied to the testing
set, exhibiting a sensitivity of 95%, a speciﬁcity of 84% and an AUC
of 0.952 (95% CI, 0.922–0.981) (Fig. 3C). Moreover, the risk score
was capable of distinguishing NSCLC cases from benign nodules
with an AUC of 0.979 (95% CI, 0.959–1.000) and sensitivity and
speciﬁcity of 95% (Fig. 3D). Taken together, the data suggest that the
ﬁve-miRNA panel is also an accurate diagnostic marker for American
patients with NSCLC.he training set and validation set. The asterisks indicate signiﬁcant differences from normal
Table 2
Risk score analysis of NSCLC cases in Chinese cohorts and American cohort.
Risk score 0–2.617 N2.617–13.820 Prediction accuracy (%)
Chinese cohorts
Controls 59 23 72
NSCLC 8 74 90
Stage I–II NSCLC 2 12 87
Training set
Controls 16 3 84
NSCLC 0 19 100
Stage I–II NSCLC 0 3 100
Validation set
Controls 43 20 68
NSCLC 8 55 87
Stage I–II NSCLC 2 9 82
American cohort
Testing (single-blind) set
Controlsa 87 17 84
NSCLC 5 103 95
Stage I–II NSCLC 3 55 95
a Including normal controls and non-cancer controls (benign nodules).
Fig. 3. Sensitivity and speciﬁcity of the ﬁve-miRNA panel in the training, validation and testing
controls in the training set. (B), ROC curve for the ﬁve-miRNA panel to discern 63 NSCLC case
to discern NSCLC cases from normal controls in the testing set. (D), ROC curve for the ﬁve-miR
1382 C. Wang et al. / EBioMedicine 2 (2015) 1377–13853.5. Assessment of Risk Score in Early-stage NSCLC
We further evaluated the potential of the ﬁve-miRNA panel to diag-
nose early-stage cancer, for which surgery is most effective. Our training
set and validation set were enriched with advanced cancers (stages III
and IV), while the testing set contained a relatively even proportion of
early-stage patients (stages I and II) (Table 1). The mean risk score of
NSCLC cases at early stages was not markedly different from that at
later stages (P N 0.05). In Chinese cohorts, 12 of 14 stage I–II tumors
had a risk score N 2.617 and an accuracy of 86%. In the testing set, using
the cutoff value of 2.617 allowed correct prediction of 55 of 58 (95%)
stage I–II tumors, demonstrating a positive performance for detecting
early stages of NSCLCs (Table 2). The results indicate that the ﬁve-
miRNA panel also functions as a strong predictor of early-stage cancer.
3.6. Logistic Regression Analysis of the Five SelectedmiRNAs and Their Panel
Finally, we conducted a forward stepwise binary logistic regression
analysis to determine whether the diagnostic usefulness of thesets. (A), ROC curve for the ﬁve-miRNA panel to discern 19 NSCLC cases from 19 normal
s from 63 normal controls in the validation set. (C), ROC curve for the ﬁve-miRNA panel
NA panel to discern 108 NSCLC cases from 56 benign nodules in the testing set.
Fig. 4. The relative contents of the selected ﬁvemiRNAs in the sera from patientwith NSCLC in the testing set. The asterisks indicate signiﬁcant differences from normal controls (P b 0.05).
⁎P b 0.05; ⁎⁎P b 0.01; ⁎⁎⁎P b 0.001.
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TNM stage, tumor subtype, sex, smoking history or age. Sensitivity anal-
yses revealed that the ﬁve-miRNA panel remained a strong predictor of
risk of NSCLC regardless of almost all subgroupings of the patients con-
sidered in both Chinese and American cohorts (Supplemental Table 6).
To further examinewhether the ﬁve alteredmiRNAs and their panel
as well as other clinical characteristics are independent potent diagnos-
ticmarkers for NSCLC,we next performed a forward stepwise univariate
logistic regression using the control group as the reference category.
Consequently, the odds ratios (ORs) for all of the ﬁve identiﬁedmiRNAs
(including miR-483-5p, miR-193a-3p, miR-214, miR-25 and miR-7)
were statistically signiﬁcant in the NSCLC cases in Chinese cohorts,
while four of the ﬁve miRNAs (including miR-483-5p, miR-193a-3p,
miR-25 andmiR-7)were independently correlatedwithNSCLC patients
in American cohort. Moreover, the panel of the ﬁve miRNAs was alsosigniﬁcant in the NSCLC patients (P b 0.001) when the cutoff value for
the panel was 2.617 in both the Chinese cohorts and American cohort
(Supplementary Table 7). These results demonstrated that the 5
miRNAs and their panel are independent potent diagnostic markers
for NSCLC. Subsequently, we also performed a multivariate logistic
regression analysis to further determine the inﬂuence of ﬁve miRNAs'
levels and clinical features on NSCLC. After adjusting for age, gender
and smoking status, we found that miR-25 (OR = 12.3, 95% CI =
1.5–101.3, P = 0.02) and the ﬁve-miRNA panel (OR = 20.0, 95% CI =
7.9–50.7, P b 0.001) were still independently associated with NSCLC in
Chinese cohorts; Furthermore, miR-25 (OR = 7.1, 95% CI = 2.1–23.9,
P = 0.001), miR-483-5p (OR = 28.6, 95% CI = 8.1–100.5, P b 0.001)
and miR-7 (OR= 91.0, 95% CI = 22.3–371.1, P b 0.001) were the inde-
pendent risk factors for NSCLC in American cohort (Supplementary
Table 7). Taken together, these results indicated that the 5 identiﬁed
1384 C. Wang et al. / EBioMedicine 2 (2015) 1377–1385miRNAs enable the detection of NSCLC and may potentially serve as
independent risk factor for NSCLC patients.
4. Discussion
To our knowledge, this study is the ﬁrst multiethnic, multicentric,
single-blind global analysis of miRNA expression patterns in the sera
from patients with NSCLC. We identiﬁed a new ﬁve-miRNA panel in
three independent cohorts from four centers in China and then
validated the miRNA panel in a large cohort from America in a blind
sensitivity trial. Our results reveal a ﬁve-miRNA panel which can serve
as a potential biomarker for diagnosing NSCLC in patients of different
races, even in the early stages of the cancer. The panel can also differen-
tiate betweenmalignant lesions and benign nodules that are frequently
found by CT scans in high-risk populations. Our ﬁndings expand upon
the results of previous studies of circulating-miRNA signatures in
patients with NSCLC.
Numerous circulating-miRNA signatures have been reported for the
detection of NSCLC, but the miRNAs identiﬁed by different groups vary
from one another (Hu et al., 2010; Bianchi et al., 2011; Chen et al.,
2012a; Heegaard et al., 2012; Wang et al., 2013). This inconsistency,
we suspect, may be attributed to the differences in study design, disease
type, sample size, methodology and especially in the method of data
normalization. Improper normalization methods may obscure real
changes and make artiﬁcial changes. In these previous studies on
NSCLC, several different normalization methods were applied in
circulating-miRNA expression analysis, including normalizing miRNA
concentrations to serum volume, or using reference genes that include
small RNAs, endogenous miRNAs or external non-human miRNAs. In
the present study, we utilized a combination of let-7d, let-7g and
let-7i as an internal reference for the normalization of serum miRNA
concentrations. In a recent study, we comprehensively assessed
let-7d/g/i and demonstrated the statistical superiority of this stable
reference gene, as it corrects for experimental variations more
effectively and achieves more accurate identiﬁcation than alternative
existing methods (Chen et al., 2013). The use of this appropriate
reference for normalization ofmiRNAs in serum improves the reproduc-
ibility and sensitivity of the results and guarantees reliable biomarker
discovery.
To realize true translational relevance and bring circulating miRNAs
into routine diagnostics, multiethnic, multicentric, and reproducibly
validated studies are indispensable. In the present study, we selected
candidate serummiRNAs in three Chinese cohortsﬁrst and then validat-
ed thewide applicability of this biomarker in a large American cohort in
a blind fashion. We found that a panel of ﬁve serummiRNAs, including
miR-483-5p, miR-193a-3p, miR-25, miR-214 and miR-7, were signiﬁ-
cantly elevated in Chinese patients with NSCLC compared with control
groups. The AUCs of ROC curve of this panel were 0.976 and 0.823 for
the two Chinese cohorts, respectively. Furthermore, in a single-blind
sensitivity trial, using a proper cutoff value of 2.617, the miRNA panel
correctly classiﬁed 103 of 108 (95%) NSCLC cases and 87 of 104 (84%)
controls from an American cohort. Our results demonstrate that the ef-
fectiveness of the ﬁve-miRNA panel is not limited to Chinese patients;
rather, the biomarker also has high sensitivity and speciﬁcity for the
diagnosis of NSCLC in American patients. Our results suggest that this
miRNA panel has potential utility as a biomarker for detecting NSCLC
in persons of different races. In addition, we observed that the Cq values
of all serum miRNAs examined in American cohort (both patients and
controls) were generally higher (approximately 3 cycles) than in the
corresponding population in Chinese cohort. This result is consistent
with a previous report that proﬁles of circulating miRNAs differed
between African Americans and European Americans, suggesting that
levels of circulating miRNAs can differ between races (Heegaard et al.,
2012). Therefore, it is critical to select a suitable internal reference for
quantiﬁcation of miRNAs in serum. The endogenous internal reference
miRNA let-7-d/g/i trio has similar characteristics to other serummiRNAs in that its average Cq value was also approximately 3 cycles
higher in American cohort than in Chinese cohorts. Therefore, when
ΔCq was calculated by subtracting the Cq values of let-7-d/g/i from
the Cq values of the target miRNAs, theΔCq values for the target miRNAs
are comparable between the Chinese American cohorts. These results fur-
ther demonstrate that a set of internal reference miRNA let-7-d/g/i may
give highly consistent results across populations and races.
One of theweaknesses in our present study is the use of pooled sam-
ples for initially global miRNA screening since results generated from
pooled samples might yield some inaccurate information and missing
useful information due to individual difference, and therefore decreases
the speciﬁcity of the test. Fortunately, by using RT-qPCR validation in a
large number of individual serum samples arranged inmultiple training
and validation sets, we successfully identiﬁed the ﬁve-miRNA panel and
additional bind trial test further conﬁrmed our ﬁndings. Nevertheless,
TLDA screening in individual sample should still be preferred and rec-
ommended in a similar study in the future. Another notably issue of
the present study is that the fold changes of the ﬁve altered miRNAs
in TLDAwere notmatchedwell with RT-qPCR analysis. The exact reason
for this inconsistence, we suspected, is because a 12-cycle pre-
ampliﬁcationwasmade in TLDA, and the fold-change of miRNA expres-
sion between NSCLC patients and control subjects might be ampliﬁed.
Therefore, the TLDA results must be validated using RT-qPCR assay
performed at an individual level of serum samples.
The diverse, complexmolecular events involved in the initiation and
development of malignant neoplasm require functional changes not
only in the tumor cell growth-related genes and/or tissue-speciﬁc
genes but also in the body's immune response-related genes. Accord-
ingly, there should be multiple miRNAs targeting those genes involved
in tumorigenesis. Circulating miRNAs can derive from the tumor itself
or from host responses to the tumor (Pritchard et al., 2012; Chen
et al., 2012b). Therefore, functionally dysregulated miRNAs in circula-
tion can be classiﬁed into three groups: (i) tissue-speciﬁc, (ii) tumor
cell growth/cycle-related, and (iii) immune response-related. Of the
ﬁve members of our predictive biomarker, miR-7 is a tissue-speciﬁc
miRNA, because it has been found to be directly involved in NSCLC
(Chou et al., 2010). miR-25, miR-483-5p and miR-193a-3p are tumor
cell growth/cycle-related miRNAs (Zhang et al., 2013; Soon et al.,
2009; Yu et al., 2015; Uhlmann et al., 2012). Finally, miR-214 may be
categorized as an immune response-related miRNA because it has
been found to play a dominant role in endothelial cell function, angio-
genesis and exosome-mediated communication between endothelial
cells (van Balkom et al., 2013; Ghalali et al., 2014; Schwarzenbach
et al., 2012). Therefore, the combination of the identiﬁed ﬁve serum
miRNAs in our study should bemore reliable and speciﬁc than the single
miRNA for the detection of NSCLC.
In conclusion, we have identiﬁed a new ﬁve-serum miRNA panel
associated with NSCLC. Speciﬁcally, we have demonstrated that this
group of serummiRNAs can potentially be used as an accurate biomark-
er for diagnosing NSCLC patients of different races. Further research is
necessary to explore whether this panel of miRNAs is also effective for
detection of NSCLC patients with other races and how much this panel
adds to serum carcinoembryonic antigen.
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